Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes.
Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. It is not yet known whether giving
fulvestrant together with trastuzumab is more effective than giving fulvestrant or
trastuzumab alone in treating breast cancer.
PURPOSE: This randomized phase II trial is studying how well fulvestrant and/or trastuzumab
works as first-line therapy in treating postmenopausal women with stage IV breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Oncology Research International
Collaborators:
AstraZeneca Genentech, Inc. University of California, Los Angeles